Geovax Labs Keeps 'Buy' Rating with $9 Price Target
ByAinvest
Thursday, Jul 17, 2025 3:32 pm ET1min read
GOVX--
July 2, 2025 - Despite recent fluctuations in its stock price, GeoVax Labs (GOVX) continues to attract positive analyst ratings. D. Boral Capital's analyst Jason Kolbert maintains a "Buy" rating and a price target of $9.00 USD for the company. This consistent rating reflects GeoVax Labs' strong market position and potential for growth.
The average one-year price target from five analysts stands at $10.70, indicating an impressive upside potential of 1,356.77% from the current price. The average brokerage recommendation is 2.0, which translates to an "Outperform" status. This consensus suggests that analysts believe in the company's long-term prospects.
However, recent market performance has shown mixed signals. According to a technical analysis report [1], GOVX has several negative signals and is within a falling trend, making it a "Strong Sell" candidate. The stock price ended at $0.7345 on July 16, 2025, after rising 6.38% from $0.6958. The technical indicators lean more towards a neutral outlook in the mid-term.
GeoVax Labs' recent focus on accelerating the development of its GEO-MVA vaccine candidate, supported by the European Medicines Agency's streamlined development pathway, is expected to bolster its market position. The company is actively engaging with global health authorities to expand access to its Mpox vaccine candidate, addressing the growing urgency of global outbreaks [2].
Despite the recent stock performance, analysts remain optimistic about GeoVax Labs' future. The company's strong IP portfolio and lead clinical programs, including its GEO-CM04S1 vaccine and Gedeptin® oncolytic therapy, position it as a key player in the biotechnology sector.
References:
[1] https://intellectia.ai/stock/GOVX/forecast
[2] https://www.nasdaq.com/press-release/geovax-highlights-growing-urgency-diversified-mpox-vaccine-supply-global-outbreaks
Geovax Labs (GOVX) maintains a "Buy" rating and price target of $9.00 USD from D. Boral Capital's analyst Jason Kolbert. The company's strong position in the market is reflected in the consistent rating and unchanged price target. The average one-year price target from 5 analysts is $10.70, with an upside of 1,356.77% from the current price. The average brokerage recommendation is 2.0, indicating an "Outperform" status.
Title: GeoVax Labs (GOVX): Analysts Maintain Positive Outlook Despite Recent Stock PerformanceJuly 2, 2025 - Despite recent fluctuations in its stock price, GeoVax Labs (GOVX) continues to attract positive analyst ratings. D. Boral Capital's analyst Jason Kolbert maintains a "Buy" rating and a price target of $9.00 USD for the company. This consistent rating reflects GeoVax Labs' strong market position and potential for growth.
The average one-year price target from five analysts stands at $10.70, indicating an impressive upside potential of 1,356.77% from the current price. The average brokerage recommendation is 2.0, which translates to an "Outperform" status. This consensus suggests that analysts believe in the company's long-term prospects.
However, recent market performance has shown mixed signals. According to a technical analysis report [1], GOVX has several negative signals and is within a falling trend, making it a "Strong Sell" candidate. The stock price ended at $0.7345 on July 16, 2025, after rising 6.38% from $0.6958. The technical indicators lean more towards a neutral outlook in the mid-term.
GeoVax Labs' recent focus on accelerating the development of its GEO-MVA vaccine candidate, supported by the European Medicines Agency's streamlined development pathway, is expected to bolster its market position. The company is actively engaging with global health authorities to expand access to its Mpox vaccine candidate, addressing the growing urgency of global outbreaks [2].
Despite the recent stock performance, analysts remain optimistic about GeoVax Labs' future. The company's strong IP portfolio and lead clinical programs, including its GEO-CM04S1 vaccine and Gedeptin® oncolytic therapy, position it as a key player in the biotechnology sector.
References:
[1] https://intellectia.ai/stock/GOVX/forecast
[2] https://www.nasdaq.com/press-release/geovax-highlights-growing-urgency-diversified-mpox-vaccine-supply-global-outbreaks
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet